作者
Sedanur K Gülsaran, Mehmet Baysal, Ufuk Demirci, Volkan Baş, Hakkı O Kirkizlar, Elif Umit, Ahmet M Demir
发表日期
2020/3
期刊
Journal of Oncology Pharmacy Practice
卷号
26
期号
2
页码范围
478-480
出版商
SAGE Publications
简介
Introduction
Ibrutinib, an oral inhibitor of Bruton’s tyrosine kinase, has altered the treatment perspective of chronic lymphocytic leukemia and showed modest activity against several types of non-Hodgkin’s lymphomas. According to phase studies and real-world data, reported serious adverse effects included atrial fibrillation, diarrhea, and bleeding diathesis. However, heart failure was not reported to be a probable adverse effect linked with ibrutinib.
Case report
In this paper, we present a 66-year-old female chronic lymphocytic leukemia patient who developed significant and symptomatic left ventricular dysfunction at the 13th month of ibrutinib treatment.
Management and outcome
Following cessation of ibrutinib, ejection fraction and clinical findings of the left ventricular dysfunction alleviated.
Discussion
Although the use of ibrutinib is generally well tolerated, cardiac functions should be monitored occasionally in all …
引用总数
20192020202120222023131
学术搜索中的文章
SK Gülsaran, M Baysal, U Demirci, V Baş, HO Kirkizlar… - Journal of Oncology Pharmacy Practice, 2020